Key result
EuroSCORE II overestimates 30-day mortality and yields a low 0.68 AUC in degenerative MR repair.
Why the study?
EuroSCORE II is widely used to predict 30-day mortality after cardiac surgery, but its discriminatory ability needed evaluation specifically in patients undergoing surgical mitral valve repair in a high-volume centre.
Is the EuroSCORE II reliable in predicting 30-day mortality in patients undergoing surgical mitral valve repair?
Cohort (n=2,645)
No
Is the EuroSCORE II reliable in predicting 30-day mortality in patients undergoing surgical mitral valve repair?
The EuroSCORE II significantly overestimates 30-day mortality in patients with degenerative mitral regurgitation undergoing surgical repair at a high-volume center, but performs well in secondary MR.
Answers are grounded in this paper and cite their sources.
Suggests caution applying EuroSCORE II to degenerative mitral regurgitation repair; leaves open need for subgroup-specific recalibration.
OBJECTIVES: The EuroSCORE II is widely used to predict 30-day mortality in patients undergoing open and transcatheter cardiac surgery. The aim of this study is to evaluate the discriminatory ability of the EuroSCORE II in predicting 30-day mortality in a large cohort of patients undergoing surgical mitral valve repair in a high-volume centre. METHODS: A retrospective review of our institutional database was carried on to find all patients who underwent mitral valve repair in our department from January 2012 to December 2019. Discrimination of the EuroSCORE II was assessed using receiver operating characteristic curves. The maximum Youden's Index was employed to define the optimal cut-point. Calibration was assessed by generating calibration plot that visually compares the predicted mortality with the observed mortality. Calibration was also tested with the Hosmer-Lemeshow goodness-of-fit test. Finally, the accuracy of the models was tested calculating the Brier score. RESULTS: A total of 2645 patients were identified, and the median EuroSCORE II was 1.3% (0.6-2.0%). In patients with degenerative mitral regurgitation (MR), the EuroSCORE II showed low discrimination (area under the curve 0.68), low accuracy (Brier score 0.27) and low calibration with overestimation of the 30-day mortality. In patients with secondary MR, the EuroSCORE II showed a good overall performance estimating the 30-day mortality with good discrimination (area under the curve 0.88), good accuracy (Brier score 0.003) and good calibration. CONCLUSIONS: In patients with degenerative MR operated on in a high-volume centre with a high level of expertise in mitral valve repair, the EuroSCORE II significantly overestimates the 30-day mortality.
No takes yet. Share an insight, caveat, or question.
Carino et al. (2020) conducted a cohort in surgical mitral valve repair (n=2,645). EuroSCORE II was evaluated on 30-day mortality (AUC 0.68 (degenerative MR); AUC 0.88 (secondary MR)). The EuroSCORE II overestimated 30-day mortality and showed low discrimination in patients with degenerative mitral regurgitation undergoing surgical repair.
Synapse has enriched 10 related papers. Consider them for comparative context: